According to the public announcement of the government service portal website of the National Drug Administration on October 9, 2022, the hrefate sodium for injection declared by the hrefate group subsidiary Shandong Runze Pharmaceutical Co., Ltd. passed the consistency evaluation.
It is reported that laxocepospore is a new semi-synthetic β-lactam broad-spectrum antibiotic. By combining with the target protein on the inner membrane of the pathogenic bacteria, the bacteria cannot maintain their morphology normally, and it also has a certain impact on division and reproduction. It is clinically used for various infectious diseases caused by the -sensitive bacteria .
lyocephalosporin is 4 to 16 times stronger than ordinary cephalosporins, and has a strong antibacterial effect on E. coli , leukocyanus leukemia, Acinetobacter genus , Proteobacteria genus; this product is mainly used for various infectious diseases caused by sensitive bacteria, such as sepsis, meningitis, respiratory infections, digestive system infections, intraperitoneal infections, urinary and reproductive system infections, skin and soft tissue infections, bone and joint infections and trauma infections.
Laxocephalos is the flagship product of Ruiying Group. The product has a broad market prospect and will become one of the strongest earnings support for Ruiying Group.
